$-0.60 EPS Expected for ESSA Pharma Inc. (EPI)

May 20, 2018 - By Louis Casey

Analysts expect ESSA Pharma Inc. (CVE:EPI) to report $-0.60 EPS on May, 21.They anticipate $6.20 EPS change or 91.18 % from last quarter’s $-6.8 EPS. After having $-1.80 EPS previously, ESSA Pharma Inc.’s analysts see -66.67 % EPS growth. The stock increased 2.20% or $0.1 during the last trading session, reaching $4.65. About 1,300 shares traded. ESSA Pharma Inc. (CVE:EPI) has 0.00% since May 20, 2017 and is . It has underperformed by 11.55% the S&P500.

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on the development of novel therapeutics for the treatment of prostate cancer. The company has market cap of $26.86 million. It is developing EPI-506 that is in Phase 1/2 clinical trials for the treatment of prostate cancer. It currently has negative earnings.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.